HUE039840T2 - Peptidkeverék - Google Patents

Peptidkeverék

Info

Publication number
HUE039840T2
HUE039840T2 HUE14828148A HUE14828148A HUE039840T2 HU E039840 T2 HUE039840 T2 HU E039840T2 HU E14828148 A HUE14828148 A HU E14828148A HU E14828148 A HUE14828148 A HU E14828148A HU E039840 T2 HUE039840 T2 HU E039840T2
Authority
HU
Hungary
Prior art keywords
peptide mixture
peptide
mixture
Prior art date
Application number
HUE14828148A
Other languages
English (en)
Inventor
Jon Amund Eriksen
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of HUE039840T2 publication Critical patent/HUE039840T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001164GTPases, e.g. Ras or Rho
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
HUE14828148A 2013-12-09 2014-12-09 Peptidkeverék HUE039840T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13196333 2013-12-09

Publications (1)

Publication Number Publication Date
HUE039840T2 true HUE039840T2 (hu) 2019-02-28

Family

ID=49765823

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14828148A HUE039840T2 (hu) 2013-12-09 2014-12-09 Peptidkeverék

Country Status (24)

Country Link
US (4) US9775892B2 (hu)
EP (5) EP3363457A1 (hu)
JP (2) JP6781403B2 (hu)
KR (1) KR20160097290A (hu)
CN (1) CN105980403A (hu)
AU (2) AU2014363643B2 (hu)
BR (1) BR112016013138A2 (hu)
CA (1) CA2933126A1 (hu)
CL (4) CL2016001405A1 (hu)
CY (1) CY1120578T1 (hu)
DK (1) DK3079715T3 (hu)
ES (1) ES2682038T3 (hu)
HR (1) HRP20181213T1 (hu)
HU (1) HUE039840T2 (hu)
IL (1) IL246007B2 (hu)
LT (1) LT3079715T (hu)
MX (1) MX2016007429A (hu)
PL (1) PL3079715T3 (hu)
PT (1) PT3079715T (hu)
RS (1) RS57623B1 (hu)
RU (1) RU2016127327A (hu)
SG (2) SG10201811172PA (hu)
SI (1) SI3079715T1 (hu)
WO (1) WO2015086590A2 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3363457A1 (en) 2013-12-09 2018-08-22 Targovax Asa A peptide mixture
AU2015257774B2 (en) 2014-05-06 2018-12-20 Targovax Solutions AS Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
CN117224710A (zh) 2017-02-01 2023-12-15 莫得纳特斯公司 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
EP3641807A4 (en) * 2017-06-22 2021-04-21 The Westmead Institute For Medical Research ADOPTIVE T-CELL THERAPY 2
BR112020025764A2 (pt) * 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
EP3841113A1 (en) * 2018-08-22 2021-06-30 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
CA3130618A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
WO2021009633A1 (en) * 2019-07-12 2021-01-21 Massey University Synthetic chromatin vaccine
CN114651001A (zh) * 2019-11-07 2022-06-21 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
KR102515083B1 (ko) 2020-12-24 2023-03-29 부산대학교 산학협력단 폴더블 페로브스카이트 태양전지 및 이의 제조 방법
CN116867799A (zh) * 2021-02-10 2023-10-10 上海吉倍生物技术有限公司 Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023220434A2 (en) * 2022-05-12 2023-11-16 The Johns Hopkins University Neoantigen vaccines for cancer prevention

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
KR101164509B1 (ko) 2002-12-16 2012-07-10 글로브이뮨 면역 요법으로서의 효모계 백신
PT1760089E (pt) 2005-09-05 2009-10-19 Immatics Biotechnologies Gmbh Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune Inc mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
EP3363457A1 (en) 2013-12-09 2018-08-22 Targovax Asa A peptide mixture
AU2015257774B2 (en) 2014-05-06 2018-12-20 Targovax Solutions AS Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent

Also Published As

Publication number Publication date
BR112016013138A2 (pt) 2018-01-16
US10335473B2 (en) 2019-07-02
US20180021419A1 (en) 2018-01-25
EP3079715B1 (en) 2018-06-13
EP3357505A1 (en) 2018-08-08
DK3079715T3 (en) 2018-09-17
RU2016127327A (ru) 2018-01-23
KR20160097290A (ko) 2016-08-17
US20170189515A1 (en) 2017-07-06
AU2014363643B2 (en) 2019-01-03
EP3363458A3 (en) 2018-11-07
AU2019201937A1 (en) 2019-04-11
EP3079715A2 (en) 2016-10-19
SI3079715T1 (en) 2018-08-31
WO2015086590A3 (en) 2015-07-30
CY1120578T1 (el) 2019-07-10
ES2682038T3 (es) 2018-09-18
JP6781403B2 (ja) 2020-11-04
EP3369432A1 (en) 2018-09-05
IL246007A (en) 2016-07-31
AU2019201937B2 (en) 2020-05-28
MX2016007429A (es) 2016-11-11
SG10201811172PA (en) 2019-01-30
US9775892B2 (en) 2017-10-03
PT3079715T (pt) 2018-08-02
CL2018000238A1 (es) 2018-06-22
JP2017502081A (ja) 2017-01-19
WO2015086590A2 (en) 2015-06-18
US10596239B2 (en) 2020-03-24
EP3363458A2 (en) 2018-08-22
US20170326218A1 (en) 2017-11-16
US10456457B2 (en) 2019-10-29
CA2933126A1 (en) 2015-06-18
CL2018000226A1 (es) 2018-06-22
AU2014363643A1 (en) 2016-07-14
EP3363457A1 (en) 2018-08-22
HRP20181213T1 (hr) 2018-10-19
IL246007B1 (en) 2023-01-01
PL3079715T3 (pl) 2018-11-30
LT3079715T (lt) 2018-08-27
CL2016001405A1 (es) 2017-03-24
US20160331820A1 (en) 2016-11-17
CN105980403A (zh) 2016-09-28
RS57623B1 (sr) 2018-11-30
JP2020023525A (ja) 2020-02-13
CL2018000232A1 (es) 2018-06-22
SG11201604644QA (en) 2016-07-28
IL246007B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
HRP20181213T1 (hr) Peptidna smjesa
HK1216757A1 (zh) 肽化合物
HRP20180452T1 (hr) Peptidi
EP2976353A4 (en) AUTOPHAGYINDUCTING PEPTIDE ANALOG
HUE050164T2 (hu) Új négy-CTL epitóp-kapcsolt peptid
HK1211596A1 (en) Peptide
GB201416171D0 (en) Fungical mixture
HK1211595A1 (en) Peptide
HK1198769A1 (en) Novel peptide
GB201315130D0 (en) Peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides